IMMUNIC, INC. (IMUX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD.

Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: -39.3M Q4 '16: -41.3M Q1 '17: -44.3M Q2 '17: -47.3M Q3 '17: -49.7M Q4 '17: -52.7M Q1 '18: -54.5M Q2 '18: -44.6M Q3 '18: -33.7M Q4 '18: -12M Q1 '19: -2.2M Q2 '19: -14.5M Q3 '19: -21.9M Q4 '19: -37M Q1 '20: -41.4M Q2 '20: -38.6M Q3 '20: -43M Q4 '20: -49M Q1 '21: -72.3M Q2 '21: -79.3M Q3 '21: -84.1M Q4 '21: -91.7M Q1 '22: -80.7M Q2 '22: -82.2M Q3 '22: -83.9M Q4 '22: -119.5M Q1 '23: -125.3M Q2 '23: -129.7M Q3 '23: -133.2M Q4 '23: -99.2M Q1 '24: -95.9M Q2 '24: -93.6M Q3 '24: -95.8M Q4 '24: -98.1M Q1 '25: -101M Q2 '25: -105.3M Q3 '25: -105.5M Q4 '25: -103.2M Q1 '26: -109.6M Q2 '26: -117.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: -39.1M Q4 '16: -41M Q1 '17: -44M Q2 '17: -46.9M Q3 '17: -49.2M Q4 '17: -52.1M Q1 '18: -41.7M Q2 '18: -32M Q3 '18: -21.3M Q4 '18: -11.5M Q1 '19: -13.6M Q2 '19: -25.6M Q3 '19: -32.1M Q4 '19: -34.9M Q1 '20: -39.1M Q2 '20: -35.9M Q3 '20: -40.5M Q4 '20: -44M Q1 '21: -70.1M Q2 '21: -76.5M Q3 '21: -82.9M Q4 '21: -92.9M Q1 '22: -79.2M Q2 '22: -83.2M Q3 '22: -85.1M Q4 '22: -120.4M Q1 '23: -124.9M Q2 '23: -127M Q3 '23: -128.5M Q4 '23: -93.6M Q1 '24: -97.9M Q2 '24: -95.3M Q3 '24: -96.9M Q4 '24: -100.5M Q1 '25: -96.4M Q2 '25: -101.8M Q3 '25: -103M Q4 '25: -97.2M Q1 '26: -104.3M Q2 '26: -111.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q2 '15: -50.2M Q3 '15: -51.1M Q4 '15: -50M Q1 '16: -46.4M Q2 '16: -40.1M Q3 '16: -36M Q4 '16: -35.8M Q1 '17: -36.7M Q2 '17: -38.1M Q3 '17: -39.6M Q4 '17: -40.4M Q1 '18: -42.6M Q2 '18: -23.5M Q4 '19: -28.5M Q1 '20: -34.3M Q2 '20: -32.5M Q3 '20: -38.4M Q4 '20: -46.1M Q1 '21: -48M Q2 '21: -67.8M Q3 '21: -73.5M Q4 '21: -83.2M Q1 '22: -91M Q2 '22: -77.7M Q3 '22: -73.7M Q4 '22: -65.1M Q1 '23: -64M Q2 '23: -68.2M Q3 '23: -71.9M Q4 '23: -70.8M Q1 '24: -75.3M Q2 '24: -72.3M Q3 '24: -75.8M Q4 '24: -84.8M Q1 '25: -82.6M Q2 '25: -90.1M Q3 '25: -89.5M Q4 '25: -85.8M Q1 '26: -81.3M Q2 '26: -87.7M Q2 '16 Q3 '17 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-105M -70M -35M 0 35M 70M 105M Q2 '15: -52.5M Q3 '15: -53.4M Q4 '15: -52.3M Q1 '16: -48.2M Q2 '16: -40.6M Q3 '16: -36.4M Q4 '16: -36.3M Q1 '17: -37.4M Q2 '17: -38.8M Q3 '17: -40.3M Q4 '17: -41.1M Q1 '18: -43.1M Q2 '18: -23.8M Q4 '19: -28.6M Q1 '20: -34.3M Q2 '20: -32.6M Q3 '20: -38.6M Q4 '20: -46.3M Q1 '21: -48.2M Q2 '21: -67.9M Q3 '21: -73.6M Q4 '21: -83.3M Q1 '22: -91M Q2 '22: -77.8M Q3 '22: -73.9M Q4 '22: -65.3M Q1 '23: -64.2M Q2 '23: -68.4M Q3 '23: -72.1M Q4 '23: -71.2M Q1 '24: -75.5M Q2 '24: -72.8M Q3 '24: -76.3M Q4 '24: -85M Q1 '25: -82.9M Q2 '25: -90.3M Q3 '25: -89.6M Q4 '25: -86M Q1 '26: -81.4M Q2 '26: -88M Q2 '16 Q3 '17 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 70M 140M 210M Q1 '18: 42.4M Q1 '19: 43.7M Q1 '21: 21.2M Q2 '21: 21.7M Q3 '21: 25.3M Q1 '22: 28.1M Q2 '22: 30.2M Q3 '22: 30.6M Q1 '23: 43.7M Q2 '23: 44.4M Q3 '23: 44.6M Q1 '24: 97.3M Q2 '24: 101.3M Q3 '24: 101.3M Q1 '25: 10.1M Q2 '25: 13.2M Q3 '25: 193.9M Q1 '26: 30.1M Q2 '26: 42.5M Q1 '18 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-60.00 -40.00 -20.00 0.00 20.00 40.00 60.00 Q3 '14: -48.27 Q4 '14: -26.58 Q1 '15: -2.71 Q2 '15: -2.43 Q3 '15: -2.35 Q4 '15: -2.10 Q1 '16: -1.79 Q2 '16: -1.46 Q3 '16: -1.27 Q4 '16: -1.30 Q1 '17: -1.38 Q2 '17: -1.37 Q3 '17: -1.35 Q4 '17: -1.33 Q1 '20: -3.88 Q2 '20: -3.26 Q3 '20: -3.14 Q4 '20: -2.92 Q1 '21: -3.76 Q2 '21: -3.68 Q3 '21: -3.74 Q4 '21: -4.02 Q1 '22: -3.13 Q2 '22: -3.03 Q3 '22: -2.96 Q4 '22: -3.77 Q1 '23: -3.61 Q2 '23: -3.43 Q3 '23: -3.25 Q4 '23: -2.11 Q1 '24: -1.83 Q2 '24: -1.50 Q3 '24: -1.23 Q4 '24: -1.00 Q1 '25: -3.21 Q2 '25: -5.03 Q3 '25: -4.92 Q4 '25: -0.62 Q1 '26: 0.81 Q2 '26: 2.04 Q3 '15 Q4 '16 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.